Section Arrow
LPCN.NASDAQ
- Lipocine
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 3.3125
-0.1575 (-4.54%)
Day High 
3.49 
Prev. Close
3.47 
1-M High
3.7299 
Volume 
5.95K 
Bid
3.19
Ask
3.7
Day Low
3.3 
Open
3.49 
1-M Low
2.9101 
Market Cap 
18.57M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.5 
20-SMA 3.36 
50-SMA 3.75 
52-W High 11.79 
52-W Low 2.9101 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-1.45
Enterprise Value
20.82M
Balance Sheet
Book Value Per Share
3.92
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.20M
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.